1. From the University of Pittsburgh Cancer Institute, Division of Hematology/Oncology, Pittsburgh, PA; the University Medical Center Charité, Robert-Rössle-Klinik, Department of Hematology, Oncology and Tumorimmunology, Humboldt University Berlin, Germany; and Celgene Corporation, Warren, NJ.